Madrigal Pharmaceuticals, Inc. (MDGL) Social Stream



Madrigal Pharmaceuticals, Inc. (MDGL): $66.45

0.72 (+1.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Madrigal Pharmaceuticals Inc (MDGL) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering MDGL.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-12 11 $203 $145 $174.5 $99.42 75.52%
2021-12-30 10 $203 $145 $173.714 $99.42 74.73%
2022-02-25 9 $203 $131 $167.571 $99.42 68.55%

The Trend in the Analyst Price Target


Over the past 14 months, MDGL's average price target has gone down $2.43.

Over the past 47 weeks, MDGL's average upside potential has been 92%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-08-07 15 220 111 178.550 90.95 96.32%
2021-09-18 15 220 111 171.820 81.74 110.2%
2021-11-07 11 203 145 174.500 93.04 87.55%
2021-11-12 11 203 145 174.500 90.84 92.1%
2022-02-25 10 203 131 167.571 93.53 79.16%

MDGL Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.44 8 0 0 1 1 9

The Trend in the Broker Recommendations


Over the past 22 months, MDGL's average broker recommendation rating improved by 0.27.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for MDGL as an investment opportunity.

  • In terms of how Madrigal Pharmaceuticals Inc fares relative to all US stocks, note that its average analyst price target is higher than 428.22% of that group.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, Madrigal Pharmaceuticals Inc's number of analysts covering the stock is greater than 404.95% of them.
  • In terms of how Madrigal Pharmaceuticals Inc fares relative to stocks in the mid market cap category, note that its upside potential (average analyst target price relative to current price) is higher than 363.79% of that group.
  • In the context of Pharmaceutical Products stocks, Madrigal Pharmaceuticals Inc's variance in analysts' estimates is lower than -53.75% of them.

In the Pharmaceutical Products industry, MCRB, LYEL, and LMDX are the three stocks most similar to Madrigal Pharmaceuticals Inc regarding the price target and analyst recommendation information presented here.

Is MDGL a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7531 seconds.